School of Medicine
Showing 12,031-12,040 of 12,938 Results
-
Ronald D. Watkins
Senior Research Engineer, Rad/Radiological Sciences Laboratory
Current Role at StanfordMy current position is Senior Research Associate in the Radiological Sciences Laboratory and the Molecular Imaging Laboratory in the Department of Radiology at Stanford School of Medicine. I provide hardware, systems, and general technical support for a large group of Faculty members and many students and post docs in the development of advanced medical imaging, metabolic imaging and image-guided interventions. My training background is primarily in RF and electrical engineering. I have spent more than 25 years in the commercial diagnostic imaging industry. Most of the projects I am currently working on involve instrumentation for metabolic imaging using magnetic deuterium imaging. I am also involved in the development of Hybrid systems that combine Positron Emission Tomography and Magnetic Resonance imaging. Other projects I am involved in use focused ultrasound for neuro-stimulation or drug delivery via blood brain barrier. I also provide RF coil design and support for small animal imaging and various research studies. I have ongoing collaborations with many other medical research institutes and Universities around the world. I currently have 45 issued US patents, and 100 pear reviewed publications.
-
Erin Watson, PsyD, ABPP
Clinical Associate Professor, Medicine - Gastroenterology & Hepatology
BioDr. Erin Watson is a board-certified clinical health psychologist and Clinical Associate Professor in the Division of Gastroenterology & Hepatology at Stanford University School of Medicine. She is a member of Stanford Health Care’s GI Behavioral Medicine program, where she specializes in the intersection of psychological health, behavioral science, and gastrointestinal and liver disease.
Dr. Watson’s clinical work focuses on helping patients navigate the emotional, behavioral, and lifestyle factors that influence medical illness. Her areas of expertise include health anxiety, stress and symptom management, health-behavior change, adjustment to chronic conditions, and the emerging specialty of psycho-hepatology. She uses practical, evidence-based approaches—including cognitive behavioral therapy, acceptance and commitment therapy, mindfulness-based interventions, and motivational interviewing—with lifestyle-medicine strategies to support long-term health and resilience. Her goal is to help patients feel more informed, supported, and empowered throughout their care.
In addition to her clinical work, Dr. Watson is engaged in research to advance behavioral treatments for chronic pain and develop new psychological interventions for individuals living with chronic liver disease. She is a co-investigator on a National Institutes of Health–funded study examining effective treatment options for veterans with chronic pain and addiction. Her scholarly work has been published in peer-reviewed journals and presented at regional and national conferences, including annual meetings of the American Psychological Association.
Dr. Watson is a Fellow of the American Academy of Clinical Health Psychology and a member of the American Psychological Association, the Society for Health Psychology (Division 38), the Society of Behavioral Medicine, the American Association for the Study of Liver Diseases, and the Rome Foundation. -
Kathleen Watson
Instructor, Psychiatry and Behavioral Sciences
BioKathleen Watson, Ph.D., currently serves as an instructor at Stanford University School of Medicine, specializing in Epidemiology and Clinical Research. She co-founded Microclinic International in 2007, where she served as Chief Operating Officer until 2012, focusing on socially-based health interventions for underserved communities.
Dr. Watson's research encompasses various aspects of mental health and metabolism. She investigates the connection between insulin resistance and depression, using computational psychiatry to uncover insights into the interplay of metabolic factors in mental well-being. Additionally, her exploration of cognitive aging examines how metabolic alterations might impact cognitive decline and related disorders. Furthermore, her research in proteomics aims to identify potential biomarkers for severe major depressive disorder. Dr. Watson has recently become a part of the Stanford Autism Center for Excellence Data Core, where she works under the guidance of Dr. Booil Jo. -
Robert Waymouth
Robert Eckles Swain Professor of Chemistry and Professor, by courtesy, of Chemical Engineering
BioRobert Eckles Swain Professor in Chemistry Robert Waymouth investigates new catalytic strategies to create useful new molecules, including bioactive polymers, synthetic fuels, and sustainable plastics. In one such breakthrough, Professor Waymouth and Professor Wender developed a new class of gene delivery agents.
Born in 1960 in Warner Robins, Georgia, Robert Waymouth studied chemistry and mathematics at Washington and Lee University in Lexington, Virginia (B.S. and B.A., respectively, both summa cum laude, 1982). He developed an interest in synthetic and mechanistic organometallic chemistry during his doctoral studies in chemistry at the California Institute of Technology under Professor R.H. Grubbs (Ph.D., 1987). His postdoctoral research with Professor Piero Pino at the Institut fur Polymere, ETH Zurich, Switzerland, focused on catalytic hydrogenation with chiral metallocene catalysts. He joined the Stanford University faculty as assistant professor in 1988, becoming full professor in 1997 and in 2000 the Robert Eckles Swain Professor of Chemistry.
Today, the Waymouth Group applies mechanistic principles to develop new concepts in catalysis, with particular focus on the development of organometallic and organic catalysts for the synthesis of complex macromolecular architectures. In organometallic catalysis, the group devised a highly selective alcohol oxidation catalyst that selectively oxidizes unprotected polyols and carbohydrates to alpha-hyroxyketones. In collaboration with Dr. James Hedrick of IBM, we have developed a platform of highly active organic catalysts and continuous flow reactors that provide access to polymer architectures that are difficult to access by conventional approaches.
The Waymouth group has devised selective organocatalytic strategies for the synthesis of functional degradable polymers and oligomers that function as "molecular transporters" to deliver genes, drugs and probes into cells and live animals. These advances led to the joint discovery with the Wender group of a general, safe, and remarkably effective concept for RNA delivery based on a new class of synthetic cationic materials, Charge-Altering Releasable Transporters (CARTs). This technology has been shown to be effective for mRNA based cancer vaccines.
